<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05031143</url>
  </required_header>
  <id_info>
    <org_study_id>FDASU-RECD-1234441</org_study_id>
    <nct_id>NCT05031143</nct_id>
  </id_info>
  <brief_title>Suprachoroidal Triamcinolone Acetonide in Harada's Retinal Detachment</brief_title>
  <official_title>Suprachoroidal Triamcinolone Acetonide Injection A Novel Therapy for Serous Retinal Detachment in Vogt-Koyanagi Harada's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Suprachoroidal injection, a novel technique for delivering ocular therapies, may facilitate&#xD;
      targeted therapeutic delivery to the choroidal and retinal structures than intravitreal&#xD;
      injection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Suprachoroidal injection, a novel technique for delivering ocular therapies, may facilitate&#xD;
      targeted therapeutic delivery to the choroidal and retinal structures than intravitreal&#xD;
      injection. Yielding high levels of corticosteroid in the retinal and choroidal layers which&#xD;
      was detectable for more than 3 months with limited exposure in the anterior segment.&#xD;
      Triamcinolone acetonide is a synthetic corticosteroid formulated as an injectable suspension&#xD;
      and has been evaluated in a number of trials to be 7.5 fold more potent anti-inflammatory&#xD;
      than cortisone. Triamcinolone acetonide enhance tight junctions between endothelial cells&#xD;
      thus reducing vessel leakage. It also has an angiostatic action by inhibition of vascular&#xD;
      endothelial growth factor and has a useful effect on many inflammatory retinal diseases. The&#xD;
      recommended dose of Triamcinolone acetonide injection is 4 mg/0.1 mL which was administrated&#xD;
      in this study. The aim of this study was to assess the efficacy of suprachoroidal&#xD;
      Triamcinolone acetonide injection (SCTA) as adjunctive therapy in the management of&#xD;
      Vogt-Koyanagi Harada's (VKH) multiple serous retinal detachment (RD) and evaluate best&#xD;
      corrected visual acuity (BCVA), intraocular pressure(IOP) and central foveal thickness (CFT)&#xD;
      by Optical Coherence Tomography (OCT) in patients diagnosed as VKH at ophthalmology clinic,&#xD;
      Benha University, EGYPT and Ebsar eye center, Benha, EGYPT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Actual">August 24, 2021</completion_date>
  <primary_completion_date type="Actual">February 20, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity (LogMAR units)</measure>
    <time_frame>6 months after injection</time_frame>
    <description>Changes in vision from baseline upto 6 months follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central Foveal Thickness measured by Optical Coherence Tomography</measure>
    <time_frame>Upto 6 months after SCTA injection</time_frame>
    <description>Changes in CFT during 6 months after injection</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intraocular pressure measured by Goldmann applanation tonometry</measure>
    <time_frame>6 months after injection</time_frame>
    <description>Changes in IOP during 6 months follow up</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Vogt Koyanagi Harada Disease</condition>
  <arm_group>
    <arm_group_label>SCTA injection (n=6 eyes)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Suprachoroidal Trimacinolone Acetonide injection 4mg/0.1ml, single dose, follow up for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-injected eyes (Standard Treatment) (n=6 eyes)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non-injected eyes on systemic steroids (standard treatment) and follow up for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suprachoroidal Triamcinolone acetonide injection for serous retinal detachment in VKH disease</intervention_name>
    <description>Suprachoroidal steroid injection for management of serous retinal detachment in VKH disease</description>
    <arm_group_label>SCTA injection (n=6 eyes)</arm_group_label>
    <other_name>SCTA for Exudative RD in VKH disease</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients diagnosed as VKH serous retinal detachment in the acute phase whom BCVA is&#xD;
             not improving after 2 weeks from starting systemic steroids.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  recent intraocular surgery.&#xD;
&#xD;
          -  patients refuse to participate in the study.&#xD;
&#xD;
          -  media opacity and other causes of serous retinal detachment than VKH.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>47 Years</minimum_age>
    <maximum_age>52 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Abdelshafy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Benha University, faculty of medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marwa Abdelshafy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Benha University, faculty of medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Anany, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Benha University, faculty of medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ophthalmology department,Benha University and Ebsar eye center,Benha,EGYPT</name>
      <address>
        <city>BanhƒÅ</city>
        <state>Qualiobeya</state>
        <zip>13511</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Ahmed Abdelshafy</investigator_full_name>
    <investigator_title>Lecturer of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Vogt-koyanagi Harada, Suprachoroidal injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveomeningoencephalitic Syndrome</mesh_term>
    <mesh_term>Retinal Detachment</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

